Comparative Pharmacology
Head-to-head clinical analysis: COREG versus METOPROLOL TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COREG versus METOPROLOL TARTRATE.
COREG vs METOPROLOL TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carvedilol is a nonselective beta-blocker with alpha1-blocking activity. It competitively blocks beta1, beta2, and alpha1 adrenergic receptors, leading to decreased cardiac output, reduced sympathetic tone, and vasodilation. It also has antioxidant and anti-proliferative properties.
Competitive beta-1 adrenergic receptor antagonist with weak beta-2 blocking activity; reduces heart rate, contractility, and AV conduction.
Heart failure: Start 3.125 mg orally twice daily; titrate up to target 25 mg twice daily as tolerated. Hypertension: Start 6.25 mg orally twice daily; increase to max 50 mg twice daily. Post-MI LV dysfunction: Start 3.125-6.25 mg orally twice daily; titrate to target 25 mg twice daily.
Initial dose 100 mg daily in divided doses (e.g., 50 mg twice daily) orally; may increase weekly up to 200-450 mg daily in 2-3 divided doses.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours in most patients, but may be prolonged in severe hepatic impairment (up to 14-18 hours). The half-life is not significantly altered in renal impairment.
3–4 hours (terminal) in healthy adults; prolonged to 7–8 hours in severe hepatic impairment; no change in renal impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 16% of the dose; fecal excretion accounts for about 84% (mainly as metabolites). Less than 2% is excreted unchanged in urine.
Renal: 95% as metabolites, <5% unchanged. Fecal: negligible.
Category C
Category C
Beta-Blocker
Beta-Blocker